Detalles de la búsqueda
1.
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Oncologist
; 27(11): 903-e834, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181763
2.
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
BMC Cancer
; 22(1): 964, 2022 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36076179
3.
Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cancer
; 126(1): 219-227, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31503343
4.
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
Oncologist
; 25(12): e1869-e1878, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32654250
5.
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
Oncologist
; 25(4): 306-e618, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297438
6.
Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials.
Int J Clin Oncol
; 24(11): 1397-1405, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31332611
7.
Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
Int J Clin Oncol
; 24(10): 1204-1213, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31062115
8.
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Cancer Sci
; 109(12): 3921-3933, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30289575
9.
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Oncology
; 94(5): 289-296, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29514163
10.
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
Int J Clin Oncol
; 22(5): 913-920, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526907
11.
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Thorac Cancer
; 14(1): 105-107, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36380738
12.
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Ther Adv Med Oncol
; 15: 17588359231177022, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37333903
13.
Effects of pericapsular soft tissue and realignment exercises for patients with osteoarthritis of the hip and Harris Hip Score below 60 points.
Curr Med Res Opin
; 38(9): 1567-1578, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35694906
14.
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.
Cancer Manag Res
; 14: 3449-3453, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36540201
15.
A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
Cancer Chemother Pharmacol
; 86(2): 285-294, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32734398
16.
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Int J Hematol
; 110(6): 675-682, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31538327
17.
Current state of yusho and prospects for therapeutic strategies.
Environ Sci Pollut Res Int
; 25(17): 16472-16480, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29197056
18.
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Int J Hematol
; 107(5): 535-540, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29362980
19.
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).
J Thorac Oncol
; 12(7): 1161-1166, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28238961
20.
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
J Am Heart Assoc
; 6(7)2017 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28684643